Anti-NKG2D/ KLRK1/ CD314 monoclonal antibody

Anti-NKG2D/ KLRK1/ CD314 antibody for FACS & in-vivo assay

Target products collectionGo to KLRK1/KLRK1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T35289-Ab-1/ GM-Tg-hg-T35289-Ab-2Anti-Human KLRK1 monoclonal antibodyHuman
GM-Tg-rg-T35289-Ab-1/ GM-Tg-rg-T35289-Ab-2Anti-Rat KLRK1 monoclonal antibodyRat
GM-Tg-mg-T35289-Ab-1/ GM-Tg-mg-T35289-Ab-2Anti-Mouse KLRK1 monoclonal antibodyMouse
GM-Tg-cynog-T35289-Ab-1/ GM-Tg-cynog-T35289-Ab-2Anti-Cynomolgus/ Rhesus macaque KLRK1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T35289-Ab-1/ GM-Tg-felg-T35289-Ab-2Anti-Feline KLRK1 monoclonal antibodyFeline
GM-Tg-cang-T35289-Ab-1/ GM-Tg-cang-T35289-Ab-2Anti-Canine KLRK1 monoclonal antibodyCanine
GM-Tg-bovg-T35289-Ab-1/ GM-Tg-bovg-T35289-Ab-2Anti-Bovine KLRK1 monoclonal antibodyBovine
GM-Tg-equg-T35289-Ab-1/ GM-Tg-equg-T35289-Ab-2Anti-Equine KLRK1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T35289-Ab-1/ GM-Tg-hg-T35289-Ab-2; GM-Tg-rg-T35289-Ab-1/ GM-Tg-rg-T35289-Ab-2;
GM-Tg-mg-T35289-Ab-1/ GM-Tg-mg-T35289-Ab-2; GM-Tg-cynog-T35289-Ab-1/ GM-Tg-cynog-T35289-Ab-2;
GM-Tg-felg-T35289-Ab-1/ GM-Tg-felg-T35289-Ab-2; GM-Tg-cang-T35289-Ab-1/ GM-Tg-cang-T35289-Ab-2;
GM-Tg-bovg-T35289-Ab-1/ GM-Tg-bovg-T35289-Ab-2; GM-Tg-equg-T35289-Ab-1/ GM-Tg-equg-T35289-Ab-2
Products NameAnti-KLRK1 monoclonal antibody
Formatmab
Target NameKLRK1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KLRK1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-566Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody
    Target AntigenProducts DevelopingMulti-species NKG2D/ KLRK1/ CD314 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLP000859human KLRK1 Lentivirus plasmid
    ORF Viral VectorvGMLP000859human KLRK1 Lentivirus particle
    ORF Viral VectorpGMLPm001912mouse Klrk1 Lentivirus plasmid
    ORF Viral VectorvGMLPm001912mouse Klrk1 Lentivirus particle


    Target information

    Target IDGM-T35289
    Target NameKLRK1
    Gene ID22914,27007,24934,100053963
    Gene Symbol and SynonymsCD314,D12S2489E,D6H12S2489E,KLR,KLRK1,NKG2-D,NKG2D,Nkrp2
    Uniprot AccessionP26718,O70215
    Uniprot Entry NameNKG2D_HUMAN,NKG2D_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseCancer
    Gene EnsemblENSG00000213809
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: KLRK1, gene name: KLRK1, also named as CD314, D12S2489E, KLR, NKG2-D, NKG2D. Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed in NK cells. This gene encodes a member of the NKG2 family. The encoded transmembrane protein is characterized by a type II membrane orientation (has an extracellular C terminus) and the presence of a C-type lectin domain. It binds to a diverse family of ligands that include MHC class I chain-related A and B proteins and UL-16 binding proteins, where ligand-receptor interactions can result in the activation of NK and T cells. The surface expression of these ligands is important for the recognition of stressed cells by the immune system, and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C, member 4) family member in the same cluster. [provided by RefSeq, Dec 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.